Detection of B-cell activating factor as a biomarker for antibody mediated rejection in transplant recipients

• US 9,176,147 B2
• Filed: 10/25/2010
• Issued: 11/03/2015
• Est. Priority Date: 10/29/2009
• Status: Expired due to Fees

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Bloom, Debra D., Sollinger, Hans W., Djamali, Arjang
• Primary Examiner(s): Bunner, Bridget E
• Application Number:
  US13/501,671
• Publication Number:
  US 20120264142A1
• Time in Patent Office: 1,835 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/52 Cytokines; Lymphokines; Interferons
• CPC Class Codes: G01N 2800/245 Transplantation related diseases, e.g. graft versus host disease
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The invention relates to methods, compositions, and kits for detection of biomarkers. In one embodiment, the invention relates to a method for detecting AMR biomarkers in a biological sample. In another embodiment, the invention relates to a method for detecting, monitoring, diagnosing and predicting antibody mediated rejection. In yet another embodiment, the invention relates to a method for monitoring a subject for antibody mediated rejection comprising detecting BAFF or a BAFF variant in a biological sample. In still another embodiment, the invention relates to a kit for detecting BAFF in a urine sample.

Claims

1. A method for monitoring a subject for antibody mediated rejection comprising:

(a) comparing an amount of B-cell activating factor (BAFF) in a urine sample obtained from a subject who has received a solid organ transplant to a reference value of BAFF in urine, wherein the reference value of BAFF in urine is from the subject prior to undergoing an organ transplant, and further wherein an increase in the amount of BAFF as compared to the reference value of BAFF in urine indicates the subject is experiencing antibody mediated rejection; and

(b) administering a medication to the subject identified in step (a) as experiencing antibody mediated rejection, wherein the medication attenuates antibody mediated rejection.

2. The method of claim 1, wherein the organ is selected from the group consisting of:

liver, heart, kidney, and lung.

3. The method of claim 2, wherein the organ is a kidney.

4. A method for determining the success of an allograft comprising:

(a) comparing an amount of B-cell activating factor (BAFF) in a urine sample obtained from a subject who has received an allograft procedure to a reference value of BAFF in urine, wherein an increase in the amount of BAFF as compared to the reference value of BAFF in urine increases the likelihood of a failed allograft; and

(b) administering a medication to the subject identified in step (a) with an increased likelihood of a failed allograft.

5. The method of claim 4, wherein the allograft is a solid organ transplantation, and further wherein the organ is selected from the group consisting of:

liver, heart, kidney, and lung.

6. The method of claim 5, wherein the organ is a kidney.

7. The method of claim 4, wherein the reference value is an average value obtained from normal subjects in a population.

8. The method of claim 4, wherein the reference value is from a subject prior to undergoing an allograft procedure.